Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.

Alzafiri R, Holcroft CA, Malolepszy P, Cohen A, Szilagyi A.

Clin Exp Gastroenterol. 2011;4:9-17. doi: 10.2147/CEG.S16168. Epub 2011 Jan 26.

2.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
3.

Colorectal adenocarcinoma in Crohn's disease: a retrospective histologic study.

Rubio CA, Befrits R.

Dis Colon Rectum. 1997 Sep;40(9):1072-8.

PMID:
9293938
4.

Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.

Thukral C, Cheifetz A, Peppercorn MA.

Drugs. 2006;66(16):2059-65. Review.

PMID:
17112300
5.

Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.

Waters HC, Vanderpoel JE, Nejadnik B, McKenzie RS, Lunacsek OE, Lennert BJ, Goff J, Augustyn DH.

J Med Econ. 2012;15(1):45-52. doi: 10.3111/13696998.2011.625746. Epub 2011 Oct 24.

PMID:
22023068
6.

Use of infliximab in pediatric patients with inflammatory bowel disease.

Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):823-8.

PMID:
11485127
7.

Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.

Magro F, Portela F.

BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. Review.

PMID:
21175228
8.

Total abdominal colectomy and ileorectal anastomosis for inflammatory bowel disease.

Pastore RL, Wolff BG, Hodge D.

Dis Colon Rectum. 1997 Dec;40(12):1455-64.

PMID:
9407985
9.

Clinical features and pattern of indeterminate colitis: Crohn's disease with ulcerative colitis-like clinical presentation.

Matsui T, Yao T, Sakurai T, Yao K, Hirai F, Matake H, Tsuda S, Wada Y, Iwashita A, Kamachi S.

J Gastroenterol. 2003;38(7):647-55.

PMID:
12898357
10.

Infliximab and ulcerative colitis.

Cottone M, Mocciaro F, Modesto I.

Expert Opin Biol Ther. 2006 Apr;6(4):401-8. Review.

PMID:
16548766
11.

Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease.

Ng SC, Arebi N, Kamm MA.

Inflamm Bowel Dis. 2007 Feb;13(2):129-34.

PMID:
17206694
12.

Interferon alpha (IFN alpha 2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohn's disease).

Ruther U, Nunnensiek C, Muller HA, Bader H, May U, Jipp P.

Hepatogastroenterology. 1998 May-Jun;45(21):691-9.

PMID:
9684118
13.

Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.

North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; Colitis Foundation of America, Bousvaros A, Antonioli DA, Colletti RB, Dubinsky MC, Glickman JN, Gold BD, Griffiths AM, Jevon GP, Higuchi LM, Hyams JS, Kirschner BS, Kugathasan S, Baldassano RN, Russo PA.

J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74.

PMID:
17460505
14.

Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.

Waters H, Vanderpoel J, McKenzie S, Lunacsek O, Franklin M, Lennert B, Goff J, Augustyn DH.

J Med Econ. 2011;14(4):397-402. doi: 10.3111/13696998.2011.583152. Epub 2011 May 19.

PMID:
21595522
15.

Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.

Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Østergaard Thomsen O, Seidelin JB.

Scand J Gastroenterol. 2012 May;47(5):518-27. doi: 10.3109/00365521.2012.660541. Epub 2012 Mar 1.

PMID:
22375898
16.

Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.

Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.

Dig Liver Dis. 2004 May;36(5):342-7.

PMID:
15191204
17.

Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.

Lawlor G, Moss AC.

Clin Exp Gastroenterol. 2009;2:149-61. Epub 2009 Dec 10.

18.

Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.

Sieczkowska J, Jarzębicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, Oracz G, Meglicka M, Kierkus J.

J Crohns Colitis. 2016 Feb;10(2):127-32. doi: 10.1093/ecco-jcc/jjv233. Epub 2015 Dec 30.

PMID:
26721942
19.

Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93.

Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I, Schulz T, Stray N, Fausa O.

Scand J Gastroenterol. 1997 Oct;32(10):1005-12.

PMID:
9361173
20.

The role of total parenteral nutrition in the management of patients with acute attacks of inflammatory bowel disease.

Seo M, Okada M, Yao T, Furukawa H, Matake H.

J Clin Gastroenterol. 1999 Oct;29(3):270-5.

PMID:
10509955
Items per page

Supplemental Content

Write to the Help Desk